Firms

aMoon
aMoon is a health technology and life-sciences investment platform operated by aMoon Ventures Y.SH. Ltd., an Israeli manager reporting to the SEC as an exempt reporting adviser (CRD300546). Its Growth strategy invests at later development and commercialization stages, while Velocity supports early-stage biomedical and healthcare technology. Edge invests in public healthcare equities; Alpha is an internal operating and value-creation team, rather than a separate fund. The platform backs computational biology, AI-enabled diagnostics and drug discovery, medical devices, and clinical care businesses including neurodevelopmental care. Its own public roster includes investment and platform staff, venture partners and external advisers; these categories are preserved. Co-founders are physician-investor Yair Schindel and Check Point co-founder Marius Nacht, whom its own site now describes as co-founder and anchor investor. Own biographies differ between2016 and2017 on the founding year, so no single year is asserted. Fund capital disclosures are kept separate from AUM, fund targets and underlying company checks. Existing historical and personally attributed investments are retained under investor2963.
- Founded
- —
- Type
- Venture capital
Funds14
aMoon Edge Limited Partnership$42M
Cayman Islands public-healthcare equity/hedge-fund vehicle managed by aMoon Ventures Y.SH. Ltd. May27,2026 SEC amendment reports cumulative securities sold USD42,575,000 to12 investors, firstsaleMarch14,2021, offeringindefinite. This is actual soldfundinterests disclosedtodate, not a finalclose, AUM ornew2026-onlyraise.
AMOON ALTR SPV LIMITED PARTNERSHIP——
Primary SEC Form ADV private-fund vehicle 805-3341415526. Actuallegalfund/feedervehicle inMarch10,2026ADV, no verified capitalclose size/date. GAVnotcopiedascash; feeder/SPVnotadditive strategy-levelcapital.
AMOON CO-INVESTMENT SPV I, L.P. (SEER)——
Primary SEC Form ADV private-fund vehicle 805-3376868213. Actuallegalfund/feedervehicle inMarch10,2026ADV, no verified capitalclose size/date. GAVnotcopiedascash; feeder/SPVnotadditive strategy-levelcapital.
AMOON CO-INVESTMENT SPV II, L.P. (SATELLITE)——
Primary SEC Form ADV private-fund vehicle 805-9328203957. Actuallegalfund/feedervehicle inMarch10,2026ADV, no verified capitalclose size/date. GAVnotcopiedascash; feeder/SPVnotadditive strategy-levelcapital.
AMOON GROWTH FUND II L.P.—$340M
Primary SEC Form ADV private-fund vehicle 805-5362193283. Manager own July2022 LinkedInfundraisemilestone explicitlyendorses340MraisedforGrowthII. Treatasreportedinterimraise, notverifiedfinalclose/date.
AMOON GROWTH FUND LIMITED PARTNERSHIP—$660M
Primary SEC Form ADV private-fund vehicle 805-1282055279. Own manager news headline explicitlyreports660Mraised for aMoonII. LegalGrowthvehicle mapped throughADV; exactclose dateNULL, notAUM orcurrentGAV.
AMOON GROWTH II FEEDER LIMITED PARTNERSHIP——
Primary SEC Form ADV private-fund vehicle 805-4634153571. Actuallegalfund/feedervehicle inMarch10,2026ADV, no verified capitalclose size/date. GAVnotcopiedascash; feeder/SPVnotadditive strategy-levelcapital.
AMOON IBX SPV L.P.——
Primary SEC Form ADV private-fund vehicle 805-7190090051. Actuallegalfund/feedervehicle inMarch10,2026ADV, no verified capitalclose size/date. GAVnotcopiedascash; feeder/SPVnotadditive strategy-levelcapital.
AMOON MDCL SPV LIMITED PARTNERSHIP——
Primary SEC Form ADV private-fund vehicle 805-2125403630. Actuallegalfund/feedervehicle inMarch10,2026ADV, no verified capitalclose size/date. GAVnotcopiedascash; feeder/SPVnotadditive strategy-levelcapital.
AMOON MTS SPV LIMITED PARTNERSHIP——
Primary SEC Form ADV private-fund vehicle 805-7695497901. Actuallegalfund/feedervehicle inMarch10,2026ADV, no verified capitalclose size/date. GAVnotcopiedascash; feeder/SPVnotadditive strategy-levelcapital.
AMOON SCPR SPV LIMITED PARTNERSHIP——
Primary SEC Form ADV private-fund vehicle 805-2305982073. Actuallegalfund/feedervehicle inMarch10,2026ADV, no verified capitalclose size/date. GAVnotcopiedascash; feeder/SPVnotadditive strategy-levelcapital.
AMOON VELOCITY FUND LIMITED PARTNERSHIP——
Primary SEC Form ADV private-fund vehicle 805-3423611100. Actuallegalfund/feedervehicle inMarch10,2026ADV, no verified capitalclose size/date. GAVnotcopiedascash; feeder/SPVnotadditive strategy-levelcapital.
AMOON VRCT SPV LIMITED PARTNERSHIP——
Primary SEC Form ADV private-fund vehicle 805-9203548495. Actuallegalfund/feedervehicle inMarch10,2026ADV, no verified capitalclose size/date. GAVnotcopiedascash; feeder/SPVnotadditive strategy-levelcapital.
CREDIT SUISSE AMOON 2 SCA SICAR——
Primary SEC Form ADV private-fund vehicle 805-1622308635. Actuallegalfund/feedervehicle inMarch10,2026ADV, no verified capitalclose size/date. GAVnotcopiedascash; feeder/SPVnotadditive strategy-levelcapital.
Team
Operations and support
Adam KotzenPrincipal |
Bar KatzirReceptionist |
Claudia FilozofExternal Adviser |
Daniel SassAssociate |
David DubinskyController |
David EsraAnalyst |
David ShulkinExternal Adviser |
Gaby HirschVP Investor Relations |
Hagai Marmor-KolletAssociate |
Irena KatsmanChief Financial Officer |
Isaac DevashVenture Partner |
Karin ZaumExecutive Assistant |
Keren DitkovskyBookkeeper |
Lloyd MinorExternal Adviser |
Maayan JanusMarketing Communications Manager |
Marius NachtCo-Founder & Anchor Investor (published own biography) |
Masha ShermanOperations Manager & Executive Assistant |
Michael ShermanExternal Adviser |
Moshic MorGeneral Partner |
Natalie ChazonExecutive Assistant |
Nataly LipovyakSenior Bookkeeper |
Noah LassonChief Compliance Officer & CISO |
Noam WaldoksChief Legal Officer |
Osnat TiroshChief People Officer & Chief of Staff |
Patrick RiversPortfolio Manager |
Rebecca PeretzExecutive Assistant |
Reut ShemaPartner |
Rey MozerAssociate |
Robert LangerExternal Adviser |
Roy WiesnerPartner |
Samuel MoedVenture Partner |
Sarit TannenbaumAssistant Controller |
Shachar EliasIntern |
Sharon FeldmanAnalyst |
Todd SoneGeneral Partner |
Tomer BerkovitzManaging Partner |
Yair SchindelCo-Founder & Managing Partner |
Yaron DanielyGeneral Partner & Head of aMoon Alpha |
Yodfat MelzerVP Finance |
Co-investing
Khosla Ventures
Ultima Genomics$— · 2022-05-31
Scipher Medicine$110M · 2022-02-24
Scipher Medicine$82M · 2021-03-24- Zebra Medical Vision$30M · 2018-06-07
Nanox (Zebra Medical)$30M · 2018-06-07
Lightspeed
Air Doctor$20M · 2024-10-01
Theranica Bio-Electronics$45M · 2022-08-29
Ultima Genomics$— · 2022-05-31
MDClone$26M · 2019-08-22Theranica$35M · 2019
Samir Kaul
Connie Health$40M · 2026-06-18
Scipher Medicine$110M · 2022-02-24
Scipher Medicine$82M · 2021-03-24
Alumni Ventures
Scipher Medicine$110M · 2022-02-24
Scipher Medicine$82M · 2021-03-24
Iantrek, Inc$42M · 2025-08-20
Omada Health$192M · 2022-02-23
Dolby Family Ventures- Zebra Medical Vision$30M · 2018-06-07
Nanox (Zebra Medical)$30M · 2018-06-07
Echo Health Ventures
Scipher Medicine$110M · 2022-02-24
Scipher Medicine$82M · 2021-03-24
Intermountain Health- Zebra Medical Vision$30M · 2018-06-07
Nanox (Zebra Medical)$30M · 2018-06-07
Theranica Bio-Electronics$45M · 2022-08-29Theranica$35M · 2019
Northpond Ventures
Scipher Medicine$110M · 2022-02-24
Scipher Medicine$82M · 2021-03-24
OurCrowd- Zebra Medical Vision$30M · 2018-06-07
Nanox (Zebra Medical)$30M · 2018-06-07
Sebastian Caliri
Hopscotch Primary Care$53M · 2026-08-18
Hopscotch Primary Care$50M · 2024-06-28
B Capital
Positive Development$51M · 2025-08-06
Bain Capital
Amylyx Pharmaceuticals$135M · 2021-07-20
Casdin Capital
Character Biosciences$93M · 2025-03-25
Catalio Capital Management
Character Biosciences$93M · 2025-03-25
Scipher Medicine$110M · 2022-02-24
Ultima Genomics$— · 2022-05-31
Positive Development$51M · 2025-08-06
Flare Capital Partners
Positive Development$51M · 2025-08-06
Founders Fund
Ultima Genomics$— · 2022-05-31
Ultima Genomics$— · 2022-05-31
Healthworx
Positive Development$51M · 2025-08-06
Scipher Medicine$110M · 2022-02-24
Innovation Endeavors
Character Biosciences$93M · 2025-03-25
IP Group
MOBILion Systems, Inc.$60M · 2021-07-13
Jefferson Life Sciences
Character Biosciences$93M · 2025-03-25
- Zebra Medical Vision$30M · 2018-06-07
Laurion Capital Management
Scipher Medicine$110M · 2022-02-24
Luma Group
Character Biosciences$93M · 2025-03-25
Amylyx Pharmaceuticals$135M · 2021-07-20
Amylyx Pharmaceuticals$135M · 2021-07-20
Scipher Medicine$110M · 2022-02-24
Theranica Bio-Electronics$45M · 2022-08-29
Nanox (Zebra Medical)$30M · 2018-06-07
Scipher Medicine$110M · 2022-02-24
Amylyx Pharmaceuticals$135M · 2021-07-20
Air Doctor$20M · 2024-10-01
Playground Global
Ultima Genomics$— · 2022-05-31
Richard Socher- Zebra Medical Vision$30M · 2018-06-07
S32
Character Biosciences$93M · 2025-03-25
Samsung Venture Investment Corporation
Air Doctor$20M · 2024-10-01
Sanofi Ventures
Character Biosciences$93M · 2025-03-25
The Cigna Group Ventures
Omada Health$192M · 2022-02-23
Air Doctor$20M · 2024-10-01
Amylyx Pharmaceuticals$135M · 2021-07-20
Air Doctor$20M · 2024-10-01
Wing Venture Capital
Prognomiq$55M · 2020-09-15
Woodline Partners
Amylyx Pharmaceuticals$135M · 2021-07-20








































